Brief: Ocuphire Announces FDA Acceptance Of New Drug Application
13/02/2023 13:26
Feb 13 (Reuters) - Ocuphire Pharma Inc OCUP.O :
* OCUPHIRE ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION
AND
PDUFA DATE OF SEPTEMBER 28, 2023 FOR NYXOL® EYE DROPS FOR
REVERSAL OF MYDRIASIS
* OCUPHIRE PHARMA INC - FDA ASSIGNED A PRESCRIPTION DRUG
USER FEE
ACT (PDUFA) DATE OF SEPTEMBER 28, 2023
Source text for Eikon: ID:nGNX89JRdG
Further company coverage: OCUP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data